Atara Biotherapeutics (ATRA) Expected to Announce Earnings on Thursday

Atara Biotherapeutics (NASDAQ:ATRA) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect Atara Biotherapeutics to post earnings of ($3.82) per share and revenue of $16.65 million for the quarter.

Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Friday, March 7th. The biotechnology company reported ($1.19) EPS for the quarter, topping analysts’ consensus estimates of ($3.82) by $2.63. The firm had revenue of $32.75 million for the quarter, compared to the consensus estimate of $20.58 million. On average, analysts expect Atara Biotherapeutics to post $-10 EPS for the current fiscal year and $-10 EPS for the next fiscal year.

Atara Biotherapeutics Trading Down 0.3 %

ATRA stock opened at $6.92 on Wednesday. The firm has a market cap of $40.54 million, a P/E ratio of -0.27 and a beta of 0.49. Atara Biotherapeutics has a 12-month low of $5.40 and a 12-month high of $20.81. The stock’s 50 day simple moving average is $7.74 and its 200 day simple moving average is $9.67.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ATRA. TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a research report on Friday, November 29th. RODMAN&RENSHAW lowered shares of Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 21st. Rodman & Renshaw started coverage on Atara Biotherapeutics in a report on Friday, December 20th. They issued a “buy” rating and a $25.00 price target on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and set a $17.00 target price on shares of Atara Biotherapeutics in a report on Tuesday, March 11th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a report on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $17.75.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.